title: Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
abstract: This prospective study sought to identify the potential reversibility of oxaliplatin-induced peripheral neuropathy (OXAIPN) by following-up its long-term course 2 years after discontinuation of oxaliplatin (OXA)-based chemotherapy. Participants were 91 colorectal cancer patients treated with OXA-based chemotherapy. Neurological assessment, clinical Total Neuropathy Score© (TNSc©) and nerve conduction studies were performed at baseline (T0), the end of chemotherapy (T1) and 2 years (T2) after discontinuation of chemotherapy. A total of 73 of 91 (80%) patients experienced OXAIPN at T1. At a median follow-up of 25 months, persistence of chronic OXAIPN was present in 61 of 73 patients (84%) and complete resolution was present in 12 patients (17%). Longitudinal comparison of TNSc© values between T1 and T2 revealed that the overall severity of OXAIPN in those 61 patients significantly decreased over time. Median TNSc© values were nine (range: 2-15) at T1 vs. four (range: 2-12) at T2 (P < 0.001). Likewise, sensory nerve conduction measures at T2 significantly improved in all sensory nerves tested, compared with T1. Severity of OXAIPN at T2 was significantly associated (P < 0.001) with high severity of OXAIPN at T1. In conclusion, persistence of OXAIPN beyond 2 years after finishing chemotherapy is common. Clinical and neurophysiological improvement is observed, although recovery is often incomplete.
authors.affiliation: Department of Neurosciences, Sciences NPSRR, University of Padova, Padova, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Briani
authors.forename: Andreas A
authors.initials: AA
authors.lastname: Argyriou
authors.forename: Cristina
authors.initials: C
authors.lastname: Izquierdo
authors.forename: Roser
authors.initials: R
authors.lastname: Velasco
authors.forename: Marta
authors.initials: M
authors.lastname: Campagnolo
authors.forename: Paola
authors.initials: P
authors.lastname: Alberti
authors.forename: Barbara
authors.initials: B
authors.lastname: Frigeni
authors.forename: Mario
authors.initials: M
authors.lastname: Cacciavillani
authors.forename: Francesca
authors.initials: F
authors.lastname: Bergamo
authors.forename: Diego
authors.initials: D
authors.lastname: Cortinovis
authors.forename: Marina
authors.initials: M
authors.lastname: Cazzaniga
authors.forename: Jordi
authors.initials: J
authors.lastname: Bruna
authors.forename: Guido
authors.initials: G
authors.lastname: Cavaletti
authors.forename: Haralabos P
authors.initials: HP
authors.lastname: Kalofonos
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D020258:Neurotoxicity Syndromes / Q000453:epidemiology*; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D010071:Oxaloacetates; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000453:epidemiology* / Q000503:physiopathology; D011446:Prospective Studies; D020127:Recovery of Function
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil
keywords: Total Neuropathy Score© (TNS©); chronic oxaliplatin-induced peripheral neuropathy; long-term course; neurotoxicity; oxaliplatin